upadacitinib rheum
Selected indexed studies
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (Ann Rheum Dis, 2023) [PMID:36357155]
- Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. (Ann Rheum Dis, 2021) [PMID:33272960]
- JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. (Ann Rheum Dis, 2021) [PMID:33741556]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (2023) pubmed
- Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. (2021) pubmed
- Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? (2018) pubmed
- JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. (2021) pubmed
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (2024) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. (2020) pubmed
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. (2023) pubmed
- JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. (2023) pubmed
- Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. (2022) pubmed
- Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. (2023) pubmed